Šalis: Naujoji Zelandija
kalba: anglų
Šaltinis: Medsafe (Medicines Safety Authority)
Orphenadrine citrate 30 mg/mL
iNova Pharmaceuticals (New Zealand) Limited
Orphenadrine citrate 30 mg/mL
30 mg/mL
Solution for injection
Active: Orphenadrine citrate 30 mg/mL Excipient: Sodium chloride Sodium hydroxide Water for injection
Ampoule, glass, 3 x 2mL, 6 mL
Prescription
Prescription
Albemarle Corporation
Package - Contents - Shelf Life: Ampoule, glass, 3 x 2mL - 6 mL - 36 months from date of manufacture stored at or below 25°C
1969-12-31
NEW ZEALAND DATA SHEET NORFLEX TM NORFLEX Page 1 of 5 1 1 PRODUCT NAME NORFLEX 100 mg slow release tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each slow release tablet contains orphenadrine citrate 100 mg. Excipient with known effect: Lactose monohydrate For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Slow release tablet White, round, biconvex tablets marked N/X on one face and no markings on the other face. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications For the relief of stiffness and pain resulting from skeletal muscle spasm in sprains and strains, local muscle injury, prolapsed intervertebral disc, lumbago, fibrositis, non-articular rheumatism, acute torticollis, surgery, fractures, anxiety and tension. Orphenadrine citrate has also been shown to be effective for treatment of tension headache and persistent hiccoughs. 4.2 Dose and method of administration Adults Two tablets per day; one in the morning and one in the evening. Children Safety and effectiveness in children have not been established. NORFLEX is not recommended for children under 12 years. Special Populations _Elderly _ The elderly may be more susceptible to anticholinergic side effects and should be given a reduced dosage. 4.3 Contraindications x Hypersensitivity to the active substance or any of the excipients listed in section 6.1. x Glaucoma x Paralytic ileus x Pyloric or duodenal obstruction NEW ZEALAND DATA SHEET NORFLEX TM NORFLEX Page 2 of 5 x Stenosing peptic ulcers x Prostatic hypertrophy or obstruction of the prostate or bladder neck x Oesophageal spasm (megaesophagus) x Myasthenia gravis. 44.4 Special warnings and precautions for use Orphenadrine citrate should be used with caution in patients with impaired kidney or liver function, tachycardia, cardiac decompensation, coronary insufficiency or cardiac arrhythmias. Safety of continuous long-term therapy with orphenadrine has not been established. Therefore, periodic monitoring of blood, urine and liver function values is recommended if orphenadrine is pre Perskaitykite visą dokumentą